Jakob Regberg

Mr. Jakob Regberg


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2012 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JRJakob Regberg
Jakob Regberg
ASArtita Srimanee
Artita Srimanee
ULUlo Langel
Ulo Langel
Cell-penetrating peptides provide a highly promising strategy for intracellular drug delivery. One relevant clinical application of cell-penetrating peptides is cancer therapeutics. Peptide based delivery could increase the uptake of drugs in tumor cells and thereby increase the efficacy of the treatment, either of conventional small molecular drugs or oligonucleotide based therapeutics. This review is focused on the cancer applications of cell penetrating peptides as delivery systems; different aspects of drug loading, cargoes and delivery are discussed together with methods for targeted delivery, activatable cell-penetrating peptides and transducible agents coupled to cell-penetrating peptides.

16 September 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
BKBeata Kmiec
Beata Kmiec
PTPedro F. Teixeira
Pedro F. Teixeira
RBRonnie P.-A. Berntsson
Ronnie P.-A. Berntsson
MMMonika W. Murcha
Monika W. Murcha
RBRui M. M. Branca
Rui M. M. Branca
EGElzbieta Glaser
Elzbieta Glaser
Both mitochondria and chloroplasts contain distinct proteolytic systems for precursor protein processing catalyzed by the mitochondrial and stromal processing peptidases and for the degradation of targeting peptides catalyzed by presequence protease. Here, we have identified and characterized a component of the organellar proteolytic systems in Arabidopsis thaliana, the organellar oligopeptidase, OOP (At5g65620). OOP belongs to the M3A family of peptide-degrading metalloproteases. Using two independent in vivo methods, we show that the protease is dually localized to mitochondria and chloroplasts. Furthermore, we localized the OPP homolog At5g10540 to the cytosol. Analysis of peptide degradation by OOP revealed substrate size restriction from 8 to 23 aa residues. Short mitochondrial targeting peptides (presequence of the ribosomal protein L29 and presequence of 1-aminocyclopropane-1-carboxylic acid deaminase 1) and N- and C-terminal fragments derived from the presequence of the ATPase beta subunit ranging in size from 11 to 20 aa could be degraded. MS analysis showed that OOP does not exhibit a strict cleavage pattern but shows a weak preference for hydrophobic residues (F/L) at the P1 position. The crystal structures of OOP, at 1.8–1.9 Å, exhibit an ellipsoidal shape consisting of two major domains enclosing the catalytic cavity of 3,000 Å3. The structural and biochemical data suggest that the protein undergoes conformational changes to allow peptide binding and proteolysis. Our results demonstrate the complementary role of OOP in targeting-peptide degradation in mitochondria and chloroplasts. Significance Import of proteins to mitochondria and chloroplasts is essential for organelle biogenesis and organism survival. Proteins to be imported contain an N-terminal peptide targeting the protein to the correct organelle. The targeting peptides are cleaved off after the completed import. Because the free targeting peptides are potentially toxic to organellar activities, they must be removed. Here we report the identification and characterization of a unique mitochondrial and chloroplastic oligopeptidase, organellar oligopeptidase, that provides a complementary pathway for the degradation of targeting peptides and also participates in general organellar quality control mechanisms degrading the peptides produced from complete protein degradation.

1 March 2016 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
ASArtita Srimanee
Artita Srimanee
JRJakob Regberg
Jakob Regberg
MHMattias Hällbrink
Mattias Hällbrink
OVOpa Vajragupta
Opa Vajragupta
ULUlo Langel
Ulo Langel

1 April 2014 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
JRJakob Regberg
Jakob Regberg
ASArtita Srimanee
Artita Srimanee
MEMikael Erlandsson
Mikael Erlandsson
RSRannar Sillard
Rannar Sillard
DDDimitar A. Dobchev
Dimitar A. Dobchev
ULUlo Langel
Ulo Langel

1 May 2015 in Journal of Controlled Release
Verified
Journal Article
Closed access
SLStaffan Lindberg
Staffan Lindberg
JRJakob Regberg
Jakob Regberg
JEJonas Eriksson
Jonas Eriksson
HHHenrik Helmfors
Henrik Helmfors
AMAndrés Muñoz-Alarcón
Andrés Muñoz-Alarcón
ULUlo Langel
Ulo Langel

1 March 2016 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
JRJakob Regberg
Jakob Regberg
LVLuis Vasconcelos
Luis Vasconcelos
FMFatemeh Madani
Fatemeh Madani
ULUlo Langel
Ulo Langel
MHMattias Hällbrink
Mattias Hällbrink